Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DML60TN)

Drug Name
Sotalol Drug Info
Synonyms
Sotalolum; Darob mite; Sotalol Monohydrochloride; Beta-Cardone; Betapace (TN); Betapace AF (TN); Darob mite (TN); MJ-1999; Sotacor (TN); Sotalex (TN); Sotalol (INN); Sotalol [INN:BAN]; Sotalolum [INN-Latin]; D,l-Sotalol; N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide; N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide; N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide; Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-(9CI); 4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide; 4'-(1-Hydroxy-2-isopropylaminoethyl)methanesulfonanilid
Therapeutic ClassAntiarrhythmic Agents
Cross-matching ID
PubChem CID
5253
ChEBI ID
CHEMBL471
CAS Number
CAS 3930-20-9
TTD Drug ID
D04VMT
VARIDT Drug ID
DR00905
INTEDE Drug ID
DR1501
ACDINA Drug ID
D00636

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oocyte meiosis 2.03 0.00e+0 90/129 (69.77%) CDC20;MAPK1;PPP3CA;...
Valine, leucine and isoleucine degradation 1.90 1.20e-2 42/48 (87.5%) ACAT2;DLD;ABAT;...
Pentose phosphate pathway 1.88 1.20e-2 25/30 (83.33%) PGD;PFKP;TKT;...
Pyruvate metabolism 1.87 1.20e-2 41/47 (87.23%) ACAT2;DLD;ADH1B;...
Glyoxylate and dicarboxylate metabolism 1.85 2.39e-2 23/30 (76.67%) ACAT2;DLD;PCCB;...
Glutamatergic synapse 1.81 2.59e-2 97/114 (85.09%) MAPK1;PPP3CA;PPP3CB;...
Fatty acid degradation 1.79 2.56e-2 40/43 (93.02%) ACAT2;ADH1B;ACADVL;...
Long-term potentiation 1.78 2.39e-2 61/67 (91.04%) MAPK1;PPP3CA;PPP3CB;...
Terpenoid backbone biosynthesis 1.76 2.66e-2 18/22 (81.82%) ACAT2;IDI1;GGPS1;...
Propanoate metabolism 1.76 2.39e-2 30/34 (88.24%) ACAT2;DLD;ABAT;...
Serotonergic synapse 1.73 3.26e-2 97/114 (85.09%) MAPK1;PRKACB;PRKCB;...
Dopaminergic synapse 1.72 3.79e-2 115/132 (87.12%) PPP3CA;PPP3CB;PRKACB;...
Biosynthesis of unsaturated fatty acids 1.71 3.59e-2 21/27 (77.78%) SCD;FADS2;ACOT7;...
Morphine addiction 1.70 4.36e-2 80/91 (87.91%) PRKACB;PRKCB;GABBR1;...
Tryptophan metabolism 1.69 4.15e-2 35/42 (83.33%) ACAT2;DLD;KYNU;...
Citrate cycle (TCA cycle) 1.68 4.11e-2 30/30 (100%) DLD;PCK1;SUCLG1;...
Circadian entrainment 1.67 4.50e-2 85/97 (87.63%) MAPK1;RPS6KA5;PRKACB;...
GABAergic synapse 1.66 4.39e-2 76/89 (85.39%) PRKACB;PRKCB;GABBR1;...
Growth hormone synthesis, secretion and action 1.65 4.85e-2 108/119 (90.76%) MAPK1;PRKACB;GNA11;...
Tyrosine metabolism 1.65 4.61e-2 30/36 (83.33%) ADH1B;AOX1;TYRP1;...
TNF signaling pathway -1.66 4.71e-2 103/112 (91.96%) MAP2K6;CX3CL1;CSF1;...
Viral protein interaction with cytokine and cytokine re... -1.66 4.63e-2 84/100 (84%) PF4V1;TNFRSF1B;TNF;...
Bladder cancer -1.67 4.14e-2 40/41 (97.56%) HBEGF;SRC;MDM2;...
Pertussis -1.68 4.33e-2 64/76 (84.21%) C1R;IL6;IL10;...
NF-kappa B signaling pathway -1.76 1.69e-2 90/104 (86.54%) TNFRSF11A;BTK;CCL13;...
ECM-receptor interaction -1.76 1.93e-2 80/88 (90.91%) SPP1;ITGAV;ITGB6;...
Rheumatoid arthritis -1.78 1.72e-2 78/93 (83.87%) TNF;ATP6AP1;TNFSF13;...
Complement and coagulation cascades -1.92 3.18e-3 76/85 (89.41%) THBD;C5AR1;PROS1;...
IL-17 signaling pathway -1.99 1.99e-3 84/94 (89.36%) IFNG;NFKB1;MAP3K7;...
Legionellosis -2.00 0.00e+0 51/57 (89.47%) NFKB1;IL1B;HBS1L;...
Staphylococcus aureus infection -2.02 0.00e+0 72/95 (75.79%) C5AR1;FPR2;HLA-DRB1;...
Malaria -2.02 0.00e+0 44/50 (88%) TNF;GYPA;IL6;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H